Enlivex Therapeutics (ENLV) Q1 2025 earnings summary

Executive summary

• Focused on developing Allocetra™, a macrophage reprogramming immunotherapy for osteoarthritis and other inflammatory conditions.

• Reprioritized pipeline to focus on inflammatory and autoimmune indications, reducing workforce by 50% and seeking external collaborations for sepsis and oncology programs.

• No immediate risk to business from ongoing conflict in Israel, but future impacts remain uncertain.

Financial highlights

• Net loss for Q1 2025 was $3.45 million, a 17% improvement from $4.14 million in Q1 2024.

• Operating loss decreased 15% year-over-year to $3.53 million, driven by lower R&D and G&A expenses.

• Research and development expenses fell 11% to $2.55 million; general and administrative expenses dropped 13% to $954,000.

• Finance income, net, increased to $81,000 from $11,000, mainly due to interest income on deposits.

• Cash and cash equivalents plus short-term deposits totaled $20.6 million as of March 31, 2025.

• Accumulated deficit reached $130.6 million.

Outlook and guidance

• Existing resources expected to fund operations through end of 2026, including key clinical trial milestones.

• Anticipates continued operating losses and need for additional financing to support future development and commercialization.